Q2 2024 Contract Research Organizations Update
Q2 2024 Contract Research Organizations Update
M&A activity within the Contract Research Organization (CRO) sector remained strong in Q2-2024, marked by nine strategic and three financial transactions. Industry leaders are expanding their geographical footprints, bolstering data capabilities, and building upon existing service offerings to fortify competitive positioning. Concurrently, private equity firms are actively investing in the sector, exemplified by Riverside’s recent platform investment in CRIO. Provident anticipates sustained PE interest, fueled by rising demand for services and a rapidly expanding R&D pipeline (6.6% CAGR 2014 – 2024 in drug count), alongside ample opportunities to capitalize on technological enhancements and realize returns.
Increasing drug development and trial costs are driving a continued reliance on the use of outsourced pharma services vendors. As competing CROs strive to provide the most efficient drug discovery and trial solutions, many are turning to M&A to realize operational leverage and tech enhancements.
To print and download the full Contract Research Organizations Update report, please click below…